AI-generated content for informational purposes only. Not financial advice. Always do your own research.

À propos

Curaleaf Holdings (OTC: CURLF) est l'un des plus grands exploitants de cannabis multi-États aux États-Unis, opérant la culture, le traitement et les opérations de vente au détail de dispensaires dans de nombreux États avec une présence internationale importante en Europe par le biais de son acquisition d'EMMAC Life Sciences. L'entreprise a construit une plateforme intégrée verticalement avec un portefeuille de marques détenues incluant Select, Grassroots et Find, générant parmi les plus hauts revenus de toute entreprise de cannabis américaine. En tant qu'investissement, Curaleaf offre une exposition directe au marché du cannabis aux États-Unis avec une échelle opérationnelle et une diversification géographique, bien que sa cotation OTC, les défis de rentabilité persistants à l'échelle de l'industrie et l'incertitude quant au calendrier de la réforme fédérale restent des considérations importantes pour les investisseurs.

Actions du cannabis

Curaleaf est un titre de cannabis leader représentant l'un des plus grands exploitants de marijuana « plant-touching » aux États-Unis, avec un portefeuille de dispensaires et de cultures multi-États qui le positionne pour bénéficier significativement de toute légalisation fédérale ou redéclassement du cannabis.

Key Financials CURA

Prix $3.31
Variation (1J) +2.16%
Variation (30D) -7.54%
Variation (60D) +21.25%
Variation (90D) -24.43%
Variation (180D) +171.31%
Variation (1Y) +57.62%
P/E Ratio -12.26
EPS (TTM) $-0.27
Plage sur 52 semaines $0.99 — $6.98
MA sur 50 jours $3.68
Volume 355.4K

Data updated Feb 15 · Source: Twelve Data

4.2
2 reviews
Performance
4
Management Quality
3.8
Valuation
3.4
Fundamentals
3.2
Risk Profile
2.8
Claude Opus 4.6
AI Review
4.2/5

Curaleaf Holdings is the largest multi-state cannabis operator in the U.S. by revenue, with operations spanning cultivation, processing, and retail across numerous states and international markets. The company's scale provides meaningful competitive advantages in procurement, branding, and regulatory navigation.

The bull case centers on Curaleaf's market leadership position and potential federal rescheduling or legalization catalysts, evidenced by the 171% gain over six months as sentiment improved. Its extensive retail footprint and brand portfolio (Select, Grassroots) create durable competitive moats in a fragmented industry.

However, the bear case is significant. The negative P/E ratio of -12.26 and EPS of -$0.27 reflect ongoing profitability challenges common across cannabis MSOs. The stock trades well below its 52-week high of $6.98, and the 24% decline over 90 days suggests fading momentum as rescheduling timelines remain uncertain. Heavy debt loads and 280E tax burdens continue to pressure cash flows.

Curaleaf remains a top-tier cannabis play for investors with high risk tolerance, but profitability must materialize to justify current valuations. Regulatory catalysts remain the key swing factor.

Performance
4
Management Quality
3.8
Valuation
3.4
Fundamentals
3.2
Risk Profile
2.8
Feb 15, 2026
Gemini 3 Pro Preview
AI Review
4.2/5

Curaleaf Holdings maintains its status as a top-tier U.S. Multi-State Operator (MSO), distinguished by its massive geographic footprint and strategic expansion into the European market. For investors, the primary thesis rests on Curaleaf's scale advantage and its ability to capitalize on potential regulatory shifts, such as federal rescheduling. However, the company's financials reflect the broader challenges of the cannabis industry; with a trailing EPS of -$0.27 and a negative P/E ratio, profitability remains hindered by tax burdens and capital-intensive growth. The stock currently trades at $3.24, which is below its 50-day moving average of $3.68, indicating recent bearish momentum despite trading significantly above its 52-week low of $0.99. While Curaleaf represents one of the more stable vehicles for exposure to the cannabis sector, it remains a speculative investment requiring patience for regulatory clarity and improved cash flow generation.

Feb 11, 2026
Curaleaf Holdings Screenshot

Added: Feb 10, 2026

curaleaf.com

Latest from Otrai

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.

Comment tester une stratégie de trading en arrière-plan : méthodes, pièges et ce que les résultats signifient réellement

Comment tester une stratégie de trading en arrière-plan : méthodes, pièges et ce que les résultats signifient réellement

Chaque trader a une stratégie qui semble excellente dans sa tête. Le backtesting est la façon de découvrir si cela fonctionne réellement. Voici comment tester les stratégies correctement, quelles métriques comptent et pourquoi la plupart des résultats de backtesting sont trop beaux pour être vrais.